Ensifentrine

• Description :

  Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3 (IC50: 0.4 nM) is 3,440 times higher than that for PDE4 (IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Weight :

  477.565

• Molecular Formula :

  C26H31N5O4

• Notes :

  Research use only, not for human use.

• Receptor :

  ——

• CAS Number :

  1884461-72-6